In:
Journal of Diabetes Investigation, Wiley, Vol. 11, No. 2 ( 2020-03), p. 400-404
Abstract:
Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood. In the present study, we evaluated the effect of treatment with tofogliflozin for 6 months on cardiac and vascular endothelial function in 26 patients with type 2 diabetes and heart diseases. Tofogliflozin treatment significantly decreased left ventricular end‐diastolic dimensions and significantly increased flow‐mediated vasodilation. Although E/e ′ did not significantly change after treatment, the decrease observed in the E/e ′ ratio was significantly correlated with the increase in acetoacetic acid and 3‐hydroxybutyrate levels. These results suggest that sodium–glucose cotransporter 2 inhibitor might improve left ventricular dilatation and vascular endothelial function in patients with type 2 diabetes. Furthermore, it is suggested that the elevation of ketone bodies induced by sodium–glucose cotransporter 2 inhibitors might contribute to a protective effect in left ventricular diastolic dysfunction.
Type of Medium:
Online Resource
ISSN:
2040-1116
,
2040-1124
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
2542077-X
Permalink